K
KGBio
Drug Development | KGbio | Indonesia
About KGBio
A clinical-stage biotechnology company, established in 2016 as a joint venture between Kalbe Farma and Genexine, specializing in the in-licensing, clinical development, and manufacturing of biological products. The company's primary focus is on novel biologics and biosimilars for oncology and other high-specialty therapeutic areas, targeting markets outside of the US/Canada, Western Europe, and China.
KGbio's business model includes the development and manufacturing of biologics, as well as providing services for regulatory and reimbursement approvals. The company also offers contract manufacturing services, leveraging its expertise to a broader client base. By concentrating on high-value specialty areas and emerging markets, the company is positioned to address unmet medical needs in these regions.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- Jakarta, Indonesia
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about KGBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See KGBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.